

51-102F3
MATERIAL CHANGE REPORT

Item 1 Name and Address of Company

Cannabix Technologies Inc. (the "Company")
501 - 3292 Production Way
Burnaby, BC V5A 4R4

Item 2 Date of Material Change

January 12, 2021

Item 3 News Release

The news release dated January 12, 2021 was disseminated through GlobeNewswire on January 12, 2021.

Item 4 Summary of Material Change

The Company announced that United States Patent and Trademark Office (USPTO) has granted patent No. 14/689434 entitled, "Cannabis Drug Detection Device" to the Company. As a requirement under the license agreement between the Company and Cannabix Breathalyzer Inc. (a separate entity) entered into on June 5th, 2014, Company will issue 5 million common shares to Cannabix Breathalyzer Inc. as a final milestone payment, triggered by the grant of patent 14/689434 by the USPTO.

The Company announced its intent to cancel one of two license agreements with the University of Florida. In particular it will be cancelling license #A17886 in relation to patent application 16/082,220.

Item 5 Full Description of Material Change

5.1 Full Description of Material Change

A full description of the material change is described in Item 4 above and in the attached news release which was filed on SEDAR (See Appendix A).

On June 5, 2014, the Company and Cannabix Breathalyzer Inc (a private company) entered into a definitive licensing agreement for marijuana breath detection technology. The definitive licensing agreement ("Definitive Agreement") provides the Company (the "Licensee") exclusive right, title, and interest in United States Patent Application Serial No. 61/981,650 No. 1 ("Licensed Patent") from Cannabix Breathalyzer Inc. (the licensor). The territory covered in the agreement is the United States and its territories and possessions, and all other countries that are deemed to constitute the North American Continent (the "Territory"). In consideration for the Licensed Patent, the Company issued 7,500,000 common shares to current shareholders of Cannabix Breathalyzer Inc. and issued 7,500,000 warrants exercisable at \$0.075 (fully exercised by the expiry date on June 26, 2015) to Cannabix Breathalyzer Inc. The Licensee shall pay Licensor a royalty of three percent (3%) of Licensee's selling price for each Licensed Product manufactured, used, or sold by Licensee in the Territory or imported by Licensee into the Territory. Additional milestone share payments are required by the Definitive Agreement.

Additional milestone payments

The Definitive Agreement outlines share payments upon reaching the following milestones: The issuance of 7,500,000 of common shares of the Company ("Shares") within 14 business days of prototype delivery to the Company and this prototype was received and shares were issued on April 9, 2015. Furthermore, upon the future receipt of the final patent, the company will issue 5,000,000 Shares (each, a "Milestone Share") to the shareholders of Cannabix Breathalyzer Inc. US non-provisional patent application no. 14/689,434 was filed April 17, 2015. The United States Patent and Trademark Office (USPTO) granted patent No. 14/689434 entitled, "Cannabis Drug Detection Device" to the Company on January 12, 2021. As a requirement under the license agreement between the Company and Cannabix Breathalyzer Inc. (a separate entity) entered into on June 5th, 2014, Company will issue 5,000,000 Milestone Shares to the shareholders of Cannabix Breathalyzer Inc. as a final milestone payment, triggered by the grant of patent 14/689434 by the USPTO.

The Company announced its intent to cancel one of two license agreements with the University of Florida. In particular it will be cancelling license #A17886 in relation to patent application 16/082,220. On March 6, 2018 the Company originally entered into this second license agreement with the UFRF for Patent Cooperation Treaty ("PCT") application, "Device and Method for Detection of Cannabis and Other Controlled Substances Using FAIMS" (PCT 16/082,220).

Kulwant Malhi and Rajpaul Attariwala, both directors of the Company are shareholders of Cannabix Breathalyzer Inc. (a separate entity) from the Company. As a shareholder of Cannabis Breathalyzer Inc., Mr Malhi is entitled to be issued 1,750,000 Milestone Shares and Mr. Attariwala is entitled to be issued 1,250,000 Milestone Shares. The issuance of the Milestone Shares will not be a "related party transaction" within the meaning of Multilateral Instrument 61-101 *Protection of Minority Security Holders in Special Transactions* ("MI 61-101") because Mr. Malhi, Mr. Attariwala and Cannabix Breathalyzer Inc. were all arm's length parties with respect to the Company at the time the Definitive Agreement was agreed to.

5.2 Disclosure for Restructuring Transactions

N/A

Item 6 Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

N/A

Item 7 Omitted Information

None

Item 8 Executive Officer

Rav Mlait, Chief Executive Officer - (604) 551-7831

Item 9 Date of Report

January 20, 2021

Schedule A

Cannabix Technologies Granted U.S. Patent - Cannabis Drug Detection Device

Vancouver, British Columbia, January 12, 2021 -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the "Company or Cannabix") developer of the Cannabix Marijuana Breathalyzer devices for law enforcement and the workplace, announces that the United States Patent and Trademark Office (USPTO) has granted patent No. 14/689434 entitled, "Cannabis Drug Detection Device" to the Company. The Company and its patent attorneys have been pursuing this patent application since its filing in 2014. Cannabix Technologies is on the forefront in research and development to create point-of-care breath testing technologies for the detection of Δ 9-tetrahydrocannabinol ("THC") - the psychoactive component of marijuana that causes impairment.

"The intellectual property protection this THC detection patent covers, gives Cannabix a broad foundation to build upon in view of the formidable insights and technical advancements made in the field of molecular gas analysis at atmospheric pressure that we have developed since this patent was initially filed in 2014. Considering the field of breath detection of drugs is in its infancy, this patent is a useful step in our IP protection strategy" said Dr. Raj Attariwala.

In light of the granting of U.S. patent 14/689434, the Company undertaken a strategic review of its existing patent applications and will re-align its portfolio by canceling its second licence agreement with the University of Florida (UF) in relation to patent application 16/082,220. The Company will continue with its original licence agreement with UF in relation to patent 8,237,118.

As a requirement under the licence agreement between the Company and Cannabix Breathalyzer Inc. (a separate entity) entered into on June 5th, 2014, Company will issue 5 million common shares to Cannabix Breathalyzer Inc. as a final milestone payment, triggered by the grant of patent 14/689434 by the USPTO.

On behalf of the Board of Directors

"Rav Mlait"

CEO
Cannabix Technologies Inc.

For further information, contact the Company at info@cannabixtechnologies.com

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to complete financings; (iv) the ability of the Company to develop and market its future product; and (v) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company's public announcements and filings. There is no assurance that the marijuana breathalyzer business will provide any benefit to the Company, and no assurance that any proposed new products will be built or proceed. There is no assurance that existing "patent pending" technologies licensed by the Company will receive patent status by regulatory authorities. The Company is not currently selling commercial breathalyzers. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.